Reported about 10 hours ago
H.C. Wainwright has maintained its Buy rating for Vertex Pharmaceuticals (NASDAQ:VRTX) following promising results from the American Diabetes Association conference, where 83% of participants in Vertex’s zimislecel program achieved insulin independence. With a price target set at $550, the evaluation highlights the treatment's efficacy and Vertex’s strategic expansion beyond cystic fibrosis therapies.
Source: YAHOO